JacobsLDBeckRWSimonJH. Intramuscular interferon beta-1A therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med2000; 343: 898–904.
2.
ComiGMartinelliVRodegherM. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler2013; 19: 1074–1083.
3.
KinkelRDontchevMKollmanC. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: A 10-year follow-up of the controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol2012; 69: 183–190.
4.
EdanGKapposLMontalbanX. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry2014; 85: 1183–1189.
5.
BermelRANaismithRT. Using MRI to make informed clinical decisions in multiple sclerosis care. Curr Opin Neurol2015; 28: 244–249.
6.
LublinFDCofieldSSCutterGR. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol2013; 73: 327–340.
7.
TintoreMRoviraÀRíoJ. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015; 138: 1863–1874.
8.
BrexPACiccarelliOO’RiordanJI. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med2002; 346: 158–164.
